Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset CGC

Coverage 166,705 Raw stories ingested 21,933 rewritten in CS_CZ • 0 to rewrite (last 2 days).

Symbols 2,793 Assets with fetched stories

Cryptocurrencies BTC 7,350 ETH 4,859 XRP 3,279 SOL 2,984 HYPE 1,761 USDC 1,589

Stocks NVDA 1,794 SPCX 1,457 MU 1,327 MSFT 1,297 AAPL 1,062 TSLA 1,027

Commodities GOLD 550 SILVER 294 OIL 101 PLATINUM 14 PALLADIUM 4 COPPER 3

Forex EURUSD 499 GBPUSD 378 USDCAD 150 USDJPY 146 AUDUSD 99 USDCHF 63

2,195 with rewritten stories in CS_CZ • Hot assets ranked by fetched stories.

Agents 7 Live Pipeline agents

FMP Stock News Fetch every minute 18s ago
FMP Forex News Fetch every 5 min 3m ago
CoinGecko News Fetch every 5 min 18s ago
FIO Stock News Fetch every 10 min 3m ago
Patria Stock News Fetch every 10 min 3m ago
Editorial rewrite Rewrite every minute running now
Asset sync Assets every 1 hour 32m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

Category Source Ticker

Relevance

Clear

Details	Date	Content	Source	Relevance
	Saved 2026-09-07 12:15 2d ago Published 2026-09-07 07:20 2d ago	Canopy Growth zvýšila tržby o 13 %, zůstává ve ztrátě Canopy Growth zvýšila tržby meziročně o 13 % na 58,9 milionu USD, ale akcie reagovaly jen minimálně. Firma stále není zisková a za čtvrtletí prodělala 10,6 milionu USD. CGC Canopy Growth	FMP Stock News	78
Original source text Canopy Growth (CGC -0.02%) grew its revenue by 13% year over year to $58.9 million in its fiscal 2027 first quarter, but the stock barely reacted because investors have seen plenty of nascent Canopy turnarounds that never quite materialized. To be sure, the company's improvements weren't limited to the top line. Its adjusted gross margin increased from 25% in the prior-year period to 31%, while its adjusted EBITDA loss narrowed by 59% to $2.3 million. Canadian medical cannabis revenue increased 22%, adult-use cannabis sales grew 10%, and international cannabis sales rose 10%. But Canopy Growth still isn't profitable. The muted response The company lost $10.6 million during the quarter (which ended June 30), while its free cash outflow increased to $18.6 million, up from $8.4 million a year earlier. That's a problem for a company that has spent years burning cash, restructuring operations, and issuing more shares of stock to raise funds. Premium Feature Moneyball Superscore 36/100 Today's Change ( -0.02 %) $ -0.00 Current Price $ 0.97 There's another wrinkle, too. Some of Canopy's growth this year came from its acquisition of MTL Cannabis. The company specifically attributed portions of its Canadian medical and adult-use growth to the acquisition. So that 13% top-line increase doesn't mean Canopy's existing businesses suddenly returned to double-digit organic growth. That may help explain the market's muted response to the quarterly report. Image source: Getty Images. The market clearly wasn't looking for another quarter where Canopy simply lost less money. It was hoping for evidence that the business will eventually be able to support itself without continually consuming cash. The latest results suggest that Canopy is moving in that direction. But after years of disappointment, investors aren't giving management much credit for promises. If revenue continues growing, margins improve, and cash burn starts falling, the stock could become more interesting. Until then, 13% revenue growth is encouraging, but it's not enough to prove Canopy's turnaround has finally arrived. Jeff Siegel has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
	Saved 2026-08-12 08:54 28d ago Published 2026-08-12 03:02 28d ago	Canopy Growth zrychluje evropskou expanzi po akvizici MTL Canopy Growth po akvizici MTL Cannabis a úsporách přes C$30 milionů zrychluje expanzi v Evropě, hlavně v Německu, Polsku a Británii. V Evropě chce zvýšit roční tempo zhruba C$10 milionů za čtvrtletí, tedy asi C$40 milionů ročně, na více než C$100 milionů. CGC Canopy Growth	FMP Stock News	78
Original source text The 2026 Cannabis Wildcard: How Tax Reform Could Reset Stock ValuationsCanopy Growth NASDAQ: CGC is positioning itself for further expansion in medical cannabis, European markets and Canadian recreational cannabis after restructuring operations, reducing costs and acquiring MTL Cannabis, President and CEO Luc Mongeau said during a Canaccord Genuity presentation. Mongeau, who has served as CEO for 18 months, said the company has shifted its focus toward operating as a consumer cannabis business rather than prioritizing cash management and pursuing opportunities across too many markets. He said Canopy reduced costs by more than C$30 million, refinanced the organization, strengthened its management team and acquired MTL Cannabis. Get Canopy Growth alerts: Constellation Brands: A Fallen Star or a Hidden Value Play?“We are really taking the next few critical step to position Canopy Growth to really win in the global cannabis market,” Mongeau said. Growth Across Canadian and European Operations Mongeau said Canopy holds the No. 1 position in Canadian medical cannabis and has improved its standing in the Canadian adult-use market. The company was ranked No. 10 in Canadian recreational cannabis when he joined, moved to No. 8 after streamlining operations and now ranks No. 6 following the MTL Cannabis acquisition, according to Mongeau. Its goal is to become a top-three player in the market. Profit from the Green Wave: Top Cannabis Stocks to WatchWhile acknowledging that Canadian recreational cannabis is a relatively mature market, Mongeau described it as a roughly C$5 billion market growing at 3% to 5%. He expects the industry to consolidate, noting that more than 1,000 licensed producers currently operate in Canadian recreational cannabis. He said the market could ultimately be led by approximately seven major participants. For fiscal 2026, Canopy reported 20% growth in Canadian adult-use cannabis and 18% growth in its medical business, Mongeau said. For the first quarter of fiscal 2027, he said consolidated revenue rose 13%, including: 10% growth in Europe; 10% growth in Canadian recreational cannabis; 22% growth in Canadian medical cannabis; and 6% growth at Storz & Bickel, its medical vaporizer business. Mongeau also said the company’s gross margin reached 31% in its latest quarterly results, representing a 600-basis-point improvement from the prior year. During the discussion, the operator characterized the most recent margin level as “36-ish percent,” but Mongeau specifically cited 31% during his presentation. MTL Cannabis Acquisition Targets Flower Supply and Quality A central component of Canopy’s strategy is improving cultivation output and flower quality. Mongeau said Canopy had not historically treated cultivation as a core operational priority, which contributed to supply constraints and inconsistent availability in international markets. MTL Cannabis brought cultivation expertise and “passion for the plant” into the company, Mongeau said. Canopy is investing in systems, processes and capital expenditures intended to increase yields and production by as much as 30%, creating additional supply for markets including Europe. “You need great flower consistently to win,” Mongeau said, adding that the company’s operating reviews and systems are now centered on producing higher-quality flower. Chief Financial Officer Tom Stewart said less than 20% of Canopy’s flower production is currently exported. He said the company is integrating MTL’s operations with Canopy’s facilities and production footprint to eliminate overlap, reduce costs and improve the quality of products supplied to consumers and patients. Canopy has three cultivation facilities and is converting a hybrid facility to fully indoor cultivation, Mongeau said. The company is cultivating in Canada at facilities certified under European Union Good Manufacturing Practice, or EU GMP, standards. Europe Seen as Major Opportunity Mongeau identified Europe as Canopy’s largest near-term opportunity, particularly Germany, Poland and the United Kingdom. He said Canopy has invested in sales teams, distribution relationships, brands and connections with pharmacists and doctors, but its progress in Europe had been hampered by inventory shortages. In Poland, Canopy recently returned to inventory availability and rose to the No. 3 market position, Mongeau said. The company is also making its first shipment to the United Kingdom during the current quarter, with related sales expected to appear in the third quarter. Canopy’s European business is currently operating at approximately C$10 million per quarter, or about C$40 million annually, according to Mongeau. He said the company is targeting a run rate of more than C$100 million, and eventually C$100 million to C$150 million annually, supported primarily by Germany. The company’s supply chain is EU GMP-compliant from cultivation through importation into Germany, repackaging and distribution, Mongeau said. He said Canopy is also working to qualify its Smiths Falls facility to produce EU GMP-compliant cannabis 2.0 products, including softgels, oils, concentrate distillates, vapes and eventually pre-rolls. Stewart said Europe offers more attractive pricing than Canada and could support premium offerings based on MTL Cannabis flower quality. Rather than compete primarily in value-priced products, Canopy plans to focus on premium categories, he said. Brands and Vaporizer Expansion Mongeau said Canopy plans to use its Tweed and Spectrum brands to compete in premium European medical cannabis segments. He said Germany continues to have a sizable price band of roughly €5 to €7 that has remained resilient despite broader pricing discussion in the market. Recent German research showed positive attitudes toward Tweed, Spectrum and MTL brands, he said. Canopy also sees expansion potential for Storz & Bickel, which Mongeau described as the leading herbal medical vaporizer company. The company is pursuing innovation in concentrate vaporizers, a category Mongeau said is substantially larger than herbal vaporizers. Overall, management said it is prioritizing cultivation, operating efficiency and a controlled expansion of its EU GMP supply chain rather than rapidly entering every emerging European market. Stewart said those foundational investments should benefit additional markets as they open. About Canopy Growth (NASDAQ:CGC)Canopy Growth Corporation is a leading Canadian cannabis company engaged in the production, distribution and sale of both medical and recreational cannabis products. Headquartered in Smiths Falls, Ontario, the company cultivates a diversified portfolio of offerings that includes dried flower, pre-rolled joints, oils, softgel capsules and edibles. Canopy Growth also markets derivative products such as beverages and wellness formulations under a range of brands, aiming to serve both patient and adult-use markets. The company operates through multiple subsidiaries, including Tweed Inc, Spectrum Therapeutics and Tokyo Smoke, each targeting distinct consumer segments. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Should You Invest $1,000 in Canopy Growth Right Now?Before you consider Canopy Growth, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Canopy Growth wasn't on the list. While Canopy Growth currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely. Get This Free Report
	Saved 2026-08-08 13:26 1mo ago Published 2026-08-08 07:15 1mo ago	Canopy Growth z přeřazení v USA moc netěží Přeřazení marihuany v USA pro Canopy Growth nemusí znamenat velký impuls, protože hlavní byznys má v Kanadě a Evropě. V USA drží investici v Canopy USA, ale bez přímé kontroly. CGC Canopy Growth	FMP Stock News	72
Original source text Canopy Growth (CGC +4.07%) is one of a handful of marijuana stocks that were all the rage early on as investors thought pot would be a huge growth market. Pot demand has grown dramatically, but marijuana stocks didn't live up to the early hype. But will that change if the classification of marijuana changes at the Federal level in the United States? Not for Canopy Growth, here's why. A slow progression for pot? Marijuana has been legal to use in an increasing number of states. Some have focused on medical use, while others have gone all the way to legalizing recreational use. That opened the way for companies to grow and sell marijuana. Image source: Getty Images. There was just one problem. Marijuana is also regulated at the Federal level. For a long time, marijuana was considered to be in the same category as heroin. Now, however, the drug has been rescheduled, putting it in the same classification as acetaminophen, an over-the-counter pain medication. While pot is still regulated, the marijuana industry's path forward is much clearer. That could open up more opportunities for growth for marijuana companies in the U.S. market. Canopy Growth isn't likely to benefit from rescheduling Canopy Growth is a pot stock, so in the big picture, rescheduling is good news. However, Canopy Growth's core operations are in Canada and Europe. With regard to the U.S. market, the company's annual report explains: We are not considered a U.S. Marijuana Issuer (as defined in the Canadian Securities Administrators Staff Notice 51-352 – Issuers with U.S. Marijuana-Related Activities (the "Staff Notice")) nor do we have material ancillary involvement in the U.S. cannabis industry in accordance with the Staff Notice. While we have an investment in Canopy USA, which is a platform that is intended to enable such U.S.-based companies that may themselves participate in the U.S. cannabis market to operate, the transaction structure was intended to ensure that we do not violate the federal laws of the United States respecting cannabis and do not allow us to participate in cannabis activities in the United States or direct the activities of Canopy USA. Where a noncontrolled affiliate has expressed an intent to enter the U.S. cannabis market, we have taken steps to insulate ourselves from all economic and voting interests. That's a lot! The summary is that Canopy Growth is an investor in Canopy USA, but it doesn't directly control Canopy USA. That's issue number one. The second issue is that Canopy USA is more focused on recreational use than medical use, which Canopy Growth explained limits the benefit that Canopy USA will see from the rescheduling. Indeed, the rescheduling was meant to increase access to the drug for medical purposes and to make it easier for companies to do research around marijuana. Making it legal for recreational purposes is a goal that is further down the road. Today's Change ( 4.07 %) $ 0.04 Current Price $ 0.97 Canopy Growth isn't in the right place at the right time What's notable is that Canopy Growth is heavily involved in the medical marijuana market in Canada. In fact, the company recently strengthened its market position there by acquiring MTL Cannabis. But the uncertain legal environment in the United States led the company to take a different approach, limiting its exposure to and business control in the U.S. market. That wasn't a bad business decision, given the circumstances and the opportunities available elsewhere. But it has left the company in a situation where U.S. rescheduling just isn't as big a deal as investors may hope. And it doesn't have as much control as investors may like to capitalize on such changes, anyway.
	Saved 2026-08-07 15:47 1mo ago Published 2026-08-07 09:36 1mo ago	Canopy Growth snížila ztrátu a překonala odhady výnosů Canopy Growth vykázala za čtvrtletí ztrátu 0,02 USD na akcii a výnosy 58,63 milionu USD, čímž překonala odhady. Ztráta byla nižší než 0,14 USD na akcii před rokem. CGC Canopy Growth	FMP Stock News	78
Original source text Canopy Growth Corporation (CGC - Free Report) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +50.00%. A quarter ago, it was expected that this company would post a loss of $0.06 per share when it actually produced a loss of $0.17, delivering a surprise of -183.33%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Canopy Growth, which belongs to the Zacks Medical - Products industry, posted revenues of $58.63 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.20%. This compares to year-ago revenues of $52.13 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Canopy Growth shares have lost about 18.2% since the beginning of the year versus the S&P 500's gain of 12.6%. What's Next for Canopy Growth?While Canopy Growth has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Canopy Growth was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.03 on $58.66 million in revenues for the coming quarter and -$0.11 on $243.57 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 34% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, FitLife Brands Inc. (FTLF - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on August 13. This company is expected to post quarterly earnings of $0.18 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. FitLife Brands Inc.'s revenues are expected to be $26.5 million, up 64.3% from the year-ago quarter.
	Saved 2026-08-07 15:47 1mo ago Published 2026-08-07 11:42 1mo ago	Canopy Growth zvýšila čisté tržby a zúžila ztrátu z upraveného EBITDA Canopy Growth v 1. čtvrtletí fiskálního roku 2027 zvýšila čisté tržby o 13 % na C$81,2 milionu a zúžila ztrátu z upraveného EBITDA na C$3,2 milionu. Hrubá marže vzrostla na 31 % z 25 %. CGC Canopy Growth	FMP Stock News	92
Original source text Canopy Growth Corporation (TSX:WEED, NYSE:CGC) reported continued revenue growth across its businesses in the first quarter of fiscal 2027, while the cannabis company narrowed its adjusted EBITDA loss from a year earlier, sending its shares 5% higher on Friday morning. Net revenue for the three months ended June 30, 2026, increased 13% year-over-year to C$81.2 million, exceeding the analyst consensus estimate of C$58.89 million. Adjusted loss per share was C$0.03, compared with the consensus estimate of a C$0.06 loss. The Smiths Falls, Ontario-based company said revenue increased across all of its businesses during the quarter. Cannabis net revenue rose 14% year-over-year to C$65.1 million. Canada medical cannabis revenue increased 22% to C$25.8 million, driven by growth in insured customers and the acquisition of MTL Cannabis, partially offset by a reduction in the Veterans Affairs Canada reimbursement rate for medical cannabis. Canada adult-use cannabis revenue increased 10% to C$29.7 million, primarily reflecting higher flower sales following the MTL Cannabis acquisition, partially offset by declines in opportunistic bulk sales. International cannabis revenue rose 10% to C$9.6 million, with Canopy Growth pointing to strength in Europe, particularly Poland. Revenue from Storz & Bickel increased 6% to C$16.1 million, which Canopy Growth attributed to prior-year product portfolio expansion and increased sales across non-core markets. Adjusted gross margin improved to 31% from 25% a year earlier, while consolidated gross margin increased to 27% from 25%. Net loss was 68% lower year-over-year, while adjusted EBITDA loss narrowed 59% to C$3.2 million. Canopy Growth attributed the improvement primarily to revenue growth across both segments and continued cost savings, partially offset by the reduction in the Veterans Affairs Canada reimbursement rate. “The renewed focus and strong momentum we established over the past year have continued into fiscal 2027,” Canopy Growth CEO Luc Mongeau said. “In the first quarter, we achieved net revenue growth in every business through solid execution across the organization. We have clear strategies to deliver further growth in each of our end markets.”
	Saved 2026-07-08 16:31 2mo ago Published 2026-07-08 11:45 2mo ago	Canopy Growth zvýšila výnosy, ale zůstává nerentabilní Canopy Growth ve fiskálním roce 2026 zvýšila výnosy o 6 % na 200,4 milionu USD a zlepšila hotovostní pozici na 256,5 milionu USD. Firma ale zůstává nerentabilní a volný peněžní tok je stále záporný. CGC Canopy Growth	FMP Stock News	72
Original source text Few stocks have destroyed as much shareholder value as Canopy Growth (CGC +0.81%). Since its 2018 peak, shares of the cannabis producer have lost more than 99% of its value as the industry struggled with oversupply, regulatory delays, and years of unprofitable growth. That kind of collapse naturally raises a question: Is this finally a buying opportunity? Moving in the right direction To be fair, Canopy Growth is a much healthier company now than it was a few years ago. Fiscal 2026 revenue increased 6% to $200.4 million, while cannabis revenue climbed 15%. Canadian medical cannabis revenue reached a record level, international cannabis sales rebounded sharply in the fourth quarter, and management continues targeting positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) during fiscal 2027. The balance sheet has also improved. Image source: Getty Images. Canopy ended fiscal 2026 with approximately $256.5 million in cash and a net cash position of $92 million, a dramatic improvement from the prior year. The company has also spent the past year reducing costs, integrating its MTL Cannabis acquisition, and narrowing operating losses. Still, despite those improvements, Canopy remains unprofitable. Better company, better stock? Revenue growth has been relatively unimpressive, free cash flow remains negative, and the investment thesis still depends heavily on broader cannabis reform and continued execution in Canada and international medical markets. None of those outcomes is guaranteed. There's also the issue of dilution. Over the years, Canopy has repeatedly issued new shares to strengthen its balance sheet and fund operations. Existing shareholders have paid a steep price for that financing, and future capital raises can't be ruled out if profitability takes longer than expected. Today's Change ( 0.81 %) $ 0.01 Current Price $ 0.96 To be sure, Canopy is certainly a stronger business than the one investors abandoned several years ago. Management deserves credit for improving the balance sheet and stabilizing operations. But a better marijuana company doesn't automatically make a better marijuana stock. Until the company demonstrates consistent profitability and positive free cash flow, I'd view the recent progress as encouraging rather than conclusive. For now, there are simply too many execution risks to call the stock a confident buy.
	Saved 2026-06-28 14:34 2mo ago Published 2026-06-28 09:15 2mo ago	Canopy Growth zvýšila tržby z lékařské marihuany Canopy Growth zvýšila tržby z lékařské marihuany o 27 % ve 4. čtvrtletí a o 17 % za celý fiskální rok. Ostatní divize ale zůstaly slabší a hrubá marže klesla. CGC Canopy Growth	FMP Stock News	78
Original source text Companies try to highlight the best news when they report earnings. That's to be expected, but you need to go into earnings season knowing you have read beyond the headlines. Canopy Growth (CGC +2.31%) reported huge growth in its medical marijuana business, which saw revenues increase 27% in the fourth quarter of fiscal 2026 and 17% for the full fiscal year. The rest of the business was a bit more mixed. The good news and the less-than-good news There's no question that Canopy Growth's medical marijuana business is doing well right now. It is also worth noting that the company recently bought MTL Cannabis, a move that should solidify its already strong position in the Canadian medical marijuana market. The strong growth in medical marijuana revenues highlights why the company is leaning into this division. Image source: Getty Images. The problem is that this isn't the company's only business. Its recreational marijuana business increased revenue by 20% in fiscal 2026, but the fourth quarter saw only a 1% increase. While the company attributes the full-year growth to "growth in infused PRJ offerings and new All-In-One vaporizers launched early in the fiscal year," the fourth quarter's 1% revenue growth suggests it ended the year on a weak note. That hints this division's outlook may not be as robust as the full-year growth suggests. Meanwhile, the company's international cannabis sales rose 68% in the quarter, but fell 7% year over year. Supply chain issues were highlighted as a problem earlier in the year. Once again, the outlook is less clear than investors may like. And then there's the Storz & Bickel vaporizer business, which saw sales decline 14% for both the full fiscal year and in the fourth quarter. Not enough good news to make Canopy Growth a buy It is likely to require more than one strong division for Wall Street to get excited about Canopy Growth again. But there's still some more bad news to consider. Notably, the company's gross margin fell four percentage points in the fourth quarter and six percentage points for the full fiscal year. Today's Change ( 2.31 %) $ 0.02 Current Price $ 0.93 Not surprisingly, Canopy Growth reported negative earnings again in fiscal 2026. In fact, it hasn't reported positive earnings since it went public, more than a decade ago. Now add in the fact that it recapitalized its balance sheet in fiscal 2026, exchanging shares for debt, and most investors should probably watch from the sidelines. Could Canopy Growth's stock rally from here? Sure. But with only one business clearly performing well, only the most aggressive investors should probably bet on this penny stock having a sustained rally. Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.